OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
Evans K, Duan J, Pritchard T, Jones CD, McDermott L, Gu Z, Toscan CE, El-Zein N, Mayoh C, Erickson SW, Guo Y, Meng F, Jung D, Rathi KS, Roberts KG, Mullighan CG, Shia CS, Pearce T, Teicher BA, Smith MA, Lock RB.
Evans K, et al. Among authors: erickson sw.
Clin Cancer Res. 2019 Jul 15;25(14):4493-4503. doi: 10.1158/1078-0432.CCR-19-0551. Epub 2019 Apr 23.
Clin Cancer Res. 2019.
PMID: 31015346
Free PMC article.